Loading viewer...
investor_presentation
Format: PDF investor_presentation
Earnings ReleaseFIRST QUARTER 2017 April 21, 2017
Earnings ReleaseFIRST QUARTER 2017
April 21, 20171Q 2017 Earnings Release
Forward Looking Statements
This report contains “forward- looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements, other than
statements of fact, that address activities, events or developments that we or our management intend, expect, project, believ e or anticipate will or may occur in
the future are forward- looking statements. Forward- looking statements are based on management’s assumptions and assessments in l ight of past experience
and trends, current economic and industry conditions, expected future developments and other relevant factors. They are not guar antees of future performance,
and actual results, developments and business decisions may differ materially from those envisaged by our forward- looking statements. Our forward- looking
statements are also subject to risks and uncertainties, which can affect our performance in both the near -and long- term. We identify the principal risks and
uncertainties that affect our performance in our Annual Report on Form 10-K and other filings with the Securities and Exchange Commission.
Non- GAAP Financial Measures
This presentation contains financial measures presented on a non- GAAP basis. Honeywell’s non- GAAP financial measures used in thi s presentation are as
follows: segment profit, on an overall Honeywell basis, a measure by which we assess operating performance, which we define as o perating income adjusted
for certain items as presented in the Appendix; segment margin, on an overall Honeywell basis, which we define as segment profit divided by sales; organic
sales growth, which we define as sales growth less the impacts from foreign currency translation and acquisitions and divestitures for the first 12 months
following transaction date; free cash flow, which we define as cash flow from operations less capital expenditures; and earni ngsper share, which we adjust to
exclude pension mark -to-market expenses and to normalize quarterly earnings per share measures for the expected full -year tax rate, as well as for other
components, such as divestitures and debt refinancings, as noted in the reconciliations presented in the Appendix. Other than references to reported earnings
per share, all references to earnings per share in this presentation are so adjusted. The respective tax rates applied when adju sting earnings per share for
these items are identified in reconciliations presented in the Appendix. Management believes that, when considered together w ithreported amounts, these
measures are useful to investors and management in understanding our ongoing operations and in the analysis of ongoing operat ingtrends. These metrics
should be considered in addition to, and not as replacements for, the most comparable GAAP measure. Refer to the Appendix att ached to this presentation for
Preview truncated — download the full document for the complete content.
investor_presentation
48 Pages
Karyopharm Therapeutics Investor Presentation — November 2021
investor_presentationinvestor_presentation
24 Pages
Karyopharm Therapeutics Inc.
United Insurance Holdings Investor Presentation May 2022
investor_presentationinvestor_presentation
14 Pages
United Insurance Holdings Corporation